



Patient, Caregiver, and Advocacy Group Survey Feedback

Purpose and privacy note: This document presents substantive feedback submitted through the 2026 patient, caregiver, and advocacy group survey for prescription drugs under review. Personally identifying and administrative information has been excluded, including respondent names, email addresses, timestamps, survey IDs, and demographic fields. Any apparent email address or telephone number found within narrative comments have also been removed. Responses are presented as submitted, with only minor spacing cleanup. The views expressed are those of individual respondents and have not been independently verified by PDAB.

Xolair (omalizumab)

Are you completing this form as:	An advocate who is also a chronic urticaria patient in remission
Is the medication currently being taken?	Previously taken but no longer on
How long has (or was) this medication taken?	3-12 months
How often do you take this medication?	Monthly
Do you have health insurance that covers this medication?	No
What is your typical out-of-pocket cost for a 30-day supply?	Not applicable
Has your out-of-pocket cost for this medication increased in the past 12 months?	No
If costs increased from last year, how significant was the increase?	Not applicable
How clear is the information you received about the cost of your medication?	Somewhat clear
Have you ever delayed filling a prescription for this medication due to cost?	Yes
Have you ever skipped doses or taken less than prescribed due to cost?	No



Have you ever stopped taking this medication due to cost?	No
Have you had difficulty obtaining this medication due to insurance requirements (e.g., prior authorization, step therapy)?	No
Have you experienced any of the following barriers? Select all that apply	Difficulty understanding insurance coverage;
How much of a financial burden is paying for this medication?	Minor burden
Have you had to cut back on other essential expenses (e.g., food, housing, utilities) to afford this medication?	No
Do you use manufacturer coupons, discount cards, or patient assistance programs to afford this medication?	Yes
Primary insurance type	Employer-sponsored
Has your insurance ever denied coverage for this medication?	No
Has your insurance required you to switch to a different medication for cost reasons?	No
Has your copay or coinsurance for this medication changed in the past year?	Not sure
Has difficulty affording this medication negatively affected your health?	No
Have you visited an emergency room or urgent care because you could not access this medication?	No
Is there anything else you would like PDAB to know about how medication costs or access affects you?	Testimony to the Prescription Drug Affordability Board Regarding Xolair Submitted by We CU, the U.S. patient advocacy organization for people with chronic urticaria Dear Members of the Prescription Drug Affordability Board,



Thank you for the opportunity to provide testimony regarding Xolair as part of the Board's 2026 drug review process.

We CU urges the Board to consider the importance of maintaining affordable and timely access to Xolair for patients who rely on this medication to manage serious and chronic health conditions. For many individuals, access to effective therapies like Xolair can make a meaningful difference in symptom control, quality of life, daily functioning, and overall health outcomes.

I say without hesitation that Xolair saved my life. I was a patient with chronic hives who was plagued by debilitating itch and anxiety. When in the throes of my flares, I had substantial difficulty working, driving, engaging with friends, bathing, even letting bed sheets and clothes touch my skin. I researched disability programs in my darkest moments as I feared I would no longer be able to work. That is no way to live, particularly when innovative treatment options are available. Xolair put me into remission and I am thankful each day I was able to access this life-changing medication.

As the Board evaluates Xolair, we encourage a balanced approach that recognizes both the financial challenges facing patients and the need to preserve access to important treatment options. Affordability efforts should ensure that patients do not face additional barriers, including higher out-of-pocket costs, coverage restrictions, delays in treatment, or administrative burdens that may prevent them from receiving care prescribed by their healthcare providers.

Patients and families are best served when prescription drug policies promote affordability while protecting access to clinically appropriate therapies. Decisions regarding Xolair should take into account the experiences of patients who depend on this treatment and the potential impact that affordability measures may have on their ability to continue



Oregon Prescription Drug
Affordability Board

	therapy. We respectfully ask the Board to prioritize policies that keep Xolair affordable and accessible for the patients who need it. We appreciate the Board's commitment to hearing from patients, caregivers, and advocates throughout this process and encourage continued consideration of the patient perspective in all affordability discussions. Thank you for your consideration.
If you could change one thing about how this prescription drug is priced or accessed in Oregon, what would it be?	
Do you currently receive prescription medications in Oregon?	No